Cargando…
Adjuvant radiation therapy in metastatic lymph nodes from melanoma
PURPOSE: To analyze the outcome after adjuvant radiation therapy with standard fractionation regimen in metastatic lymph nodes (LN) from cutaneous melanoma. PATIENTS AND METHODS: 86 successive patients (57 men) were treated for locally advanced melanoma in our institution. 60 patients (69%) underwen...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041681/ https://www.ncbi.nlm.nih.gov/pubmed/21294913 http://dx.doi.org/10.1186/1748-717X-6-12 |
_version_ | 1782198461346611200 |
---|---|
author | Bibault, Jean-Emmanuel Dewas, Sylvain Mirabel, Xavier Mortier, Laurent Penel, Nicolas Vanseymortier, Luc Lartigau, Eric |
author_facet | Bibault, Jean-Emmanuel Dewas, Sylvain Mirabel, Xavier Mortier, Laurent Penel, Nicolas Vanseymortier, Luc Lartigau, Eric |
author_sort | Bibault, Jean-Emmanuel |
collection | PubMed |
description | PURPOSE: To analyze the outcome after adjuvant radiation therapy with standard fractionation regimen in metastatic lymph nodes (LN) from cutaneous melanoma. PATIENTS AND METHODS: 86 successive patients (57 men) were treated for locally advanced melanoma in our institution. 60 patients (69%) underwent LN dissection followed by radiation therapy (RT), while 26 patients (31%) had no radiotherapy. RESULTS: The median number of resected LN was 12 (1 to 36) with 2 metastases (1 to 28). Median survival after the first relapse was 31.8 months. Extracapsular extension was a significant prognostic factor for regional control (p = 0.019). Median total dose was 50 Gy (30 to 70 Gy). A standard fractionation regimen was used (2 Gy/fraction). Median number of fractions was 25 (10 to 44 fractions). Patients were treated with five fractions/week. Patients with extracapsular extension treated with surgery followed by RT (total dose ≥50 Gy) had a better regional control than patients treated by surgery followed by RT with a total dose <50 Gy (80% vs. 35% at 5-year follow-up; p = 0.004). CONCLUSION: Adjuvant radiotherapy was able to increase regional control in targeted sub-population (LN with extracapsular extension). |
format | Text |
id | pubmed-3041681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30416812011-02-19 Adjuvant radiation therapy in metastatic lymph nodes from melanoma Bibault, Jean-Emmanuel Dewas, Sylvain Mirabel, Xavier Mortier, Laurent Penel, Nicolas Vanseymortier, Luc Lartigau, Eric Radiat Oncol Research PURPOSE: To analyze the outcome after adjuvant radiation therapy with standard fractionation regimen in metastatic lymph nodes (LN) from cutaneous melanoma. PATIENTS AND METHODS: 86 successive patients (57 men) were treated for locally advanced melanoma in our institution. 60 patients (69%) underwent LN dissection followed by radiation therapy (RT), while 26 patients (31%) had no radiotherapy. RESULTS: The median number of resected LN was 12 (1 to 36) with 2 metastases (1 to 28). Median survival after the first relapse was 31.8 months. Extracapsular extension was a significant prognostic factor for regional control (p = 0.019). Median total dose was 50 Gy (30 to 70 Gy). A standard fractionation regimen was used (2 Gy/fraction). Median number of fractions was 25 (10 to 44 fractions). Patients were treated with five fractions/week. Patients with extracapsular extension treated with surgery followed by RT (total dose ≥50 Gy) had a better regional control than patients treated by surgery followed by RT with a total dose <50 Gy (80% vs. 35% at 5-year follow-up; p = 0.004). CONCLUSION: Adjuvant radiotherapy was able to increase regional control in targeted sub-population (LN with extracapsular extension). BioMed Central 2011-02-06 /pmc/articles/PMC3041681/ /pubmed/21294913 http://dx.doi.org/10.1186/1748-717X-6-12 Text en Copyright ©2011 Bibault et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Bibault, Jean-Emmanuel Dewas, Sylvain Mirabel, Xavier Mortier, Laurent Penel, Nicolas Vanseymortier, Luc Lartigau, Eric Adjuvant radiation therapy in metastatic lymph nodes from melanoma |
title | Adjuvant radiation therapy in metastatic lymph nodes from melanoma |
title_full | Adjuvant radiation therapy in metastatic lymph nodes from melanoma |
title_fullStr | Adjuvant radiation therapy in metastatic lymph nodes from melanoma |
title_full_unstemmed | Adjuvant radiation therapy in metastatic lymph nodes from melanoma |
title_short | Adjuvant radiation therapy in metastatic lymph nodes from melanoma |
title_sort | adjuvant radiation therapy in metastatic lymph nodes from melanoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041681/ https://www.ncbi.nlm.nih.gov/pubmed/21294913 http://dx.doi.org/10.1186/1748-717X-6-12 |
work_keys_str_mv | AT bibaultjeanemmanuel adjuvantradiationtherapyinmetastaticlymphnodesfrommelanoma AT dewassylvain adjuvantradiationtherapyinmetastaticlymphnodesfrommelanoma AT mirabelxavier adjuvantradiationtherapyinmetastaticlymphnodesfrommelanoma AT mortierlaurent adjuvantradiationtherapyinmetastaticlymphnodesfrommelanoma AT penelnicolas adjuvantradiationtherapyinmetastaticlymphnodesfrommelanoma AT vanseymortierluc adjuvantradiationtherapyinmetastaticlymphnodesfrommelanoma AT lartigaueric adjuvantradiationtherapyinmetastaticlymphnodesfrommelanoma |